Literature DB >> 14615372

Hoxa9 influences the phenotype but not the incidence of Mll-AF9 fusion gene leukemia.

Ashish R Kumar1, Wendy A Hudson, Weili Chen, Ritsuo Nishiuchi, Qing Yao, John H Kersey.   

Abstract

Identification of the targets of mixed lineage leukemia (MLL) fusion genes will assist in understanding the biology of MLL fusion gene leukemias and in development of better therapies. Numerous studies have implicated HOXA9 as one of the possible targets of MLL fusion proteins. To determine if HOXA9 was required for leukemia development by MLL fusion genes, we compared the effects of the Mll-AF9 knock-in mutation in mice in the presence or absence of Hoxa9. Both groups of mice showed myeloid expansion at 8 weeks and then developed myeloid leukemia with a similar incidence and time course. The leukemia in the mice lacking Hoxa9 generally displayed a more immature myeloid phenotype than that in the mice that were wild-type for Hoxa9. Gene expression profiling revealed that expression of Mll-AF9 led to overexpression of Hoxa5, Hoxa6, Hoxa7, Hoxa9, and Hoxa10. Thus, genes of the Hox-a cluster are important in defining the phenotype but not the incidence of Mll-AF9 leukemia. These results demonstrate that the Mll-AF9 fusion gene disrupts the expression of several Hox genes, none of which as a single gene is likely to be necessary for development of leukemia. Instead, we propose that the "Hox code" minimally defined by the Hoxa5-a9 cluster is central to MLL leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14615372     DOI: 10.1182/blood-2003-07-2582

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  60 in total

1.  Grist for the MLL: how do MLL oncogenic fusion proteins generate leukemia stem cells?

Authors:  Tim C P Somervaille; Michael L Cleary
Journal:  Int J Hematol       Date:  2010-05-08       Impact factor: 2.490

2.  Down-regulation of homeobox genes MEIS1 and HOXA in MLL-rearranged acute leukemia impairs engraftment and reduces proliferation.

Authors:  Kira Orlovsky; Alexander Kalinkovich; Tanya Rozovskaia; Elias Shezen; Tomer Itkin; Hansjuerg Alder; Hatice Gulcin Ozer; Letizia Carramusa; Abraham Avigdor; Stefano Volinia; Arthur Buchberg; Alex Mazo; Orit Kollet; Corey Largman; Carlo M Croce; Tatsuya Nakamura; Tsvee Lapidot; Eli Canaani
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

3.  Protein-arginine methyltransferase 1 (PRMT1) methylates Ash2L, a shared component of mammalian histone H3K4 methyltransferase complexes.

Authors:  Jill S Butler; Cecilia I Zurita-Lopez; Steven G Clarke; Mark T Bedford; Sharon Y R Dent
Journal:  J Biol Chem       Date:  2011-02-01       Impact factor: 5.157

Review 4.  Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.

Authors:  Bin E Li; Patricia Ernst
Journal:  Exp Hematol       Date:  2014-09-28       Impact factor: 3.084

5.  Isolated Hoxa9 overexpression predisposes to the development of lymphoid but not myeloid leukemia.

Authors:  Sarah H Beachy; Masahiro Onozawa; Deborah Silverman; Yang Jo Chung; Mariela Martinez Rivera; Peter D Aplan
Journal:  Exp Hematol       Date:  2013-02-19       Impact factor: 3.084

6.  Mechanisms of mixed-lineage leukemia.

Authors:  Andrew G Muntean
Journal:  Int J Hematol Oncol       Date:  2013-06-01

Review 7.  Molecular pathogenesis of MLL-associated leukemias.

Authors:  Mariko Eguchi; Minenori Eguchi-Ishimae; Mel Greaves
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

8.  Accurate Medicine: Indirect Targeting of NPM1-Mutated AML.

Authors:  Christopher S Hourigan; Peter D Aplan
Journal:  Cancer Discov       Date:  2016-10       Impact factor: 39.397

9.  Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells.

Authors:  Weili Chen; Ashish R Kumar; Wendy A Hudson; Quanzhi Li; Baolin Wu; Rodney A Staggs; Erik A Lund; Thien N Sam; John H Kersey
Journal:  Cancer Cell       Date:  2008-05       Impact factor: 31.743

10.  HOXA9 is required for survival in human MLL-rearranged acute leukemias.

Authors:  Joerg Faber; Andrei V Krivtsov; Matthew C Stubbs; Renee Wright; Tina N Davis; Marry van den Heuvel-Eibrink; Christian M Zwaan; Andrew L Kung; Scott A Armstrong
Journal:  Blood       Date:  2008-12-03       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.